To evaluate the efficacy and tolerability of a high-dose mitoxanuniquely steep dose-response curve in clonogenic assays with trone-based induction regimen without consolidation therapy ovarian cancer and leukemic cells. 8, 9 In a preliminary study mg/m 2 ) mitoxantrone in combination with a fixed dose of
Introduction

Materials and methods
Consistently, clinical trials in patients older than 60 years with Patients 60 years of age or older, with previously untreated acute myeloid leukemia (AML) have demonstrated signifi-AML, were eligible for entry into the trial. Patients were cantly lower response rates, shorter remissions and lower required to have a normal left ventricular ejection fraction, probability of survival, compared to results in younger and serum bilirubin and creatinine less than 2 mg/dl. Patients adults.
1,2 The poor outcomes observed in older patients have with a pre-existing myelodysplastic syndrome or other antebeen attributed to both the increased frequency of adverse cedent hematological disorder were included. Cytogenetic variables which predict resistance to chemotherapy (ie unfavevaluation of the bone marrow was performed on all patients. orable chromosomal changes, presence of an antecedent Written informed consent according to institutional guidelines hematological disorder) and organ impairment or reduced was obtained prior to the initiation of treatment. performance status due to comorbidity, resulting in an All patients were treated with an induction regimen conincreased likelihood of therapy-related toxicity and death. sisting of cytarabine (Ara-C) at a dose of 3 g/m 2 by intravenous Recent strategies to improve results for patients with AML infusion over 3 h once daily on days 1-5. Patients were ranhave focused on the administration of high doses of cytarabine domized to receive mitoxantrone by intravenous infusion over (3 g/m 2 every 12 h for 3-6 days) in order to overcome resist-15 min, either 80 mg/m 2 once on day 2 (high dose) or 12 ance in leukemic cells. 4, 5 Two cooperative group trials have mg/m 2 daily on days 1-3 (standard dose). documented an enhanced antileukemic effect of high-dose Bone marrow aspirates and/or biopsies were obtained 7-10 cytarabine when given as post-remission therapy, which days after treatment to assess the effectiveness of therapy in resulted in improved survival rates in younger patients. 6, 7 This clearing the marrow of disease, and weekly thereafter to assess beneficial effect, however, was offset in older patients by remission status. Complete remission (CR) was defined as the significant treatment-related morbidity and mortality.
achievement of a cellular marrow with Ͻ5% myeloblasts, a An alternative approach has involved the administration of granulocyte count of Ͼ1 × 10 9 /l, and a platelet count of dose-intensive therapy during the initial induction period and 100 × 10 9 /l for a duration of 1 month or longer. dose escalation of drugs other than cytarabine, such as mitoxPatients achieving a CR were not given post-remission conantrone. The rationale for the administration of high-dose solidation chemotherapy, but observed monthly for relapse. mitoxantrone came from in vitro studies demonstrating a Patients failing initial therapy, or relapsing after an initial response were taken off the study. All patients were followed until death. needed. 13 Survival curves were compared using a log-rank 
Results
Patient characteristics
in the blood or bone marrow for more than 3 months prior to treatment of AML, was present in 20 of 54 patients. None had From February 1991 to May 1994, 54 adults with newly diagsecondary AML or previous chemotherapy. nosed AML were enrolled in the study (Table 1 ). The median age of patients entered was 70 years (range 60-83). Five patients (two in the group receiving the lower dose and three Induction response and toxicity in the other) were aged 60-65. Unfavorable cytogenetics (−5, −7, +8 or other miscellaneous abnormalities) were seen in 18
Of the 54 patients treated, 53 were evaluable for response and of 54 patients, and an ECOG performance status of Ͼ1 was toxicity. Response is shown in Table 2 . Overall, 27 (50%, with recorded in 15 of 54 patients. An antecedent hematological 95% confidence limits 36-64%) achieved a complete disorder (AHD), characterized as a documented abnormality remission. There was 16/28 CR in patients receiving high-dose mitoxantrone compared to 11/26 with standard-dose mitoxantrone. All patients achieving CR had an aplastic marrow 7-10 As expected, severe myelosuppression was universal. The median time to achievement of CR was 26 days and 31 days,
Sex
Male 34 17 17 respectively, for high-and standard-dose mitoxantrone (range ally (four patients).
2-3 15 9 6 Apart from myelosuppression, mucositis was the most FAB M subtype significant adverse effect (Table 3) anorexia and epigastric pain was generally mild and was con- 
Remission duration and survival
The data reported from this trial have demonstrated that higher than standard doses of cytarabine and mitoxantrone The median follow-up for patients on the study is 13 months (range 1-36). Median time to relapse was 6 months (7 and 5 could be administered to patients over the age of 60 without incurring a substantial increase in morbidity and mortality. months for the high-dose and low-dose group, respectively). Of the 39 patients who either failed initial induction or Apart from a somewhat higher incidence of stomatitis, the non-hematological toxicity associated with this regimen was relapsed following a CR, 25 underwent salvage chemotherapy. Of these, six achieved a subsequent complete not worse than what was observed in those who received 36 mg/m 2 . Similarly, the median times to CR were not different remission for the duration of 1-24 months.
Actuarial survival is shown in Figure 1 . Median survival for between the two arms of the study, suggesting that there was no increase in the toxicity to normal hematopoietic cells. all patients is 8 months. It was 9 months for high-dose mitoxantrone and 6 months for the standard-dose group. Median
Conclusions regarding the efficacy of high-dose mitoxantrone in this patient population are less clear. The differences relapse-free survival (RFS) for all patients, including failures, was 3 months in the low-dose and 5 months in the high-dose between high-dose and standard-dose mitoxantrone in CR rate, disease-free survival, and overall survival consistently group. Median overall and relapse-free survival probability was 9 and 6 months, respectively, when considering only appeared to favor treatment with high-dose mitoxantrone. However, the study was designed to detect or exclude a very those patients who achieved a CR.
Survival and relapse-free survival probability curves were large difference in survival, and the available data do not allow us to confirm or reject lesser differences with complete two to four cycles of standard-dose cytarabine.
2,21
Those who do undergo consolidation therapy frequently sufficient power.
The results of previous dose-intensive induction studies in require additional hospitalization for management of infection and other chemotherapy-related complications. Death during older patients with untreated AML are summarized in Table  4 . Kahn et al, 11 using an attenuated dose/schedule of highconsolidation therapy in older patients occurred in 5-14%. 21, 22 dose cytarabine (12-16 g/m 2 ) as a single agent, observed only one CR in 17 patients with seven induction deaths. In the Since the overwhelming majority of relapsed or refractory patients in the present study either failed subsequent salvage GIMEMA study, the administration of a higher cumulative dose of cytarabine (18-24 g/m 2 ) with l-asparaginase resulted therapy or did not receive any, it can be concluded that the major impact on survival came from the initial treatment, not in a higher CR rate without an apparent increase in induction mortality but persistent leukemia remained the major cause of from salvage therapy. This experience suggests that patients given a single induction treatment can achieve an outcome induction failure. 16 Using maximally tolerated doses of cytarabine (up to 36 g/m 2 ), both Lazarus et al 12 and Preisler et al 17 similar to that following standard-dose treatment with repetitive consolidation, and be spared the potential morbidity and reported enhanced antileukemic efficacy with substantial gastrointestinal and cerebellar toxicity, and high (38-48%) inducmortality of additional chemotherapy. This is likely to result in an improved quality of life as well as less cost. 23 These tion mortality rates. The regimen used in our study included lower cumulative doses of cytarabine (15 g/m 2 ), administered potential benefits would need to be documented in a future trial specifically designed to address these endpoints. once daily, in combination with full doses (36 mg/m 2 ) of mitoxantrone in half the patients and high doses (80 mg/m
2 ) The present study, however, failed to improve complete response and median survival expectations over those in the other half. The CR rate with this regimen compares favorably to that seen with higher doses of cytarabine, but with reported with standard regimens. Rather than more chemotherapy, better survival in elderly patients may ultimately lower toxicity and lower induction mortality. Although persistent leukemia was a more frequent cause of induction failure depend on the development of more effective chemotherapy, and the use of non-chemotherapeutic post-remission strategies in our study (28%) as compared to others using maximal doses of cytarabine, increasing the dose of cytarabine in our regimen which can be safely implemented in older patients. 24, 25 in an attempt to improve antileukemic activity might not necessarily translate into a higher remission rate, because of a parallel increase in induction deaths. Although the value References of growth factors following standard-dose induction in elderly patients has been demonstrated, the question whether their
